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Abstract 
A 25-year-old man was diagnosised subcuta-
neous  panniculitis-like  T-cell  lymphoma
(SPTCL) through biopsy of a nodule from the
anterior chest. After the treatment with pred-
nisone 90 mg 3 weeks and tapered off in 1
month,  the  disease  released,  but  relapsed
together  with  symptions  of  hemophagocytic
syndrome eight months after the termination
of  prednisone.  CHOEP  recipe  was  given  but
with  unsatisfactory  result  until  cyclosporine
was prescribed. Cyclosporine was removed 6
months later. There is no evidence of clinical
relapse  1  year  later.  This  case  suggest  that
cyclosporine could be a selectable treatment
even in relapsed SPTCL.
Introduction
According the latest iteration of the WHO
classification,  subcutaneous  panniculitis-like
T-cell lymphoma(SPTCL) is refer to αβ T-cell
derivation cytotoxic tumor.1 Multiple subcuta-
neous  nodules  of  varying  size  or  necrotic,
mostly located on the trunk, and extremities,
may be misdiagnosed as panniculitis because
of it’s deceptively benign appearance.2,3 SPTCL
affects both man and women with a broad age
range, but rarely in children younger than 2
years.4
Some  literatures  about  the  treatment  of
SPTCL have been published, but no scheme
was involved in relapsed SPTCL. Herein, we
introduce a relapsed SPTCL was successfully
cured by cyclosporin A.
Case Report
A 25-year-old man presented with a 1-month
history  of  recurrent,  multiple,  reddish  skin
lesions and nodules on the anterior chest sur-
face  together  with  low-grade  fever,  general
fatigue and anorexia. A deep punch biopsy of a
nodule  from  the  anterior  chest  verified  the
diagnosis  of  SPTCL,  immunohistochemistry
showed the neoplastic cells were positive for:
LCA, CD3, CD8, granzyme B, and perforin, and
negative for CD56 and CD20. The symptions
improved in 4 days and disappeared in 1 week
after prednisone 90 mg daily was given inter-
mittently -which maintained 3 weeks and was
tapered off in 6 weeks. But the same lesions
and nodules was founded in the same location
with 4-kg weight loss eight months after the
termination  of  prednisone.  The  patient  was
admitted to our hospital with the examination
of  pale,  and  febrile(temperature  of  39°C).
Local skin examination revealed multiple ery-
thematous,  tender,  and  firm  subcutaneous
nodules of variable size (1-1.5 cm) on the ante-
rior chest. Physical examination, chest X ray,
CT scan of abdomen, and bone marrow studies,
revealed no other site involvement. There was
moderate hepatosplenomegaly. Mucous mem-
branes were free of lesions. Laboratory investi-
gations showed pancytopenia, an elevated ery-
throcyte sedimentation rate (66 mm/h), nor-
mal  renal  function  tests,  abnormal  hepatic
function tests (alanine aminotransferase 188
U/L, aspartate aminotransferase 236 U/L, alka-
line  phosphatase  635  U/L,  total  bilirubin  98
μmol/L,  conjugated  bilirubin  22  μmol/L,  and
high  triglycerides  465  mg/dL.  Prothrombin
time and activated partial thromboplastin time
is 26 sec., 48 sec. respectively; fibrinogen is 74
mg/dL;  and  positive  fibrinogen  degradation
products were also noted. Throat, midstream
urine, and blood culture results were negative.
Serologic tests for syphilis, HIV, and hepatitis
B and C viruses were negative. Tuberculin and
Coombs  tests  were  negative.  The  α1-anti  -
trypsin level was normal. Antinuclear and anti-
smith antibodies, rheumatoid factor, and cryo-
globulins were negative. CT showed moderate
hepatospleno  megaly.  Bone  marrow  aspirate
showed  hemophagocytosis  of  red  blood  cells
and neutrophils by histiocytes. 
A  diagnosis  of  SPTCL  together  HPS  was
made and a CHOEP recipe -cyclophosphamide
〔750 mg/m2, intravenously (i.v.), doxorubicin
(50 mg/m2 i.v.), vincristine (2 mg i.v.) all given
on day 1 and prednisone (90 mg/day per os)
given on days 1-5, etoposide 100 mg/m2 i.v. on
days 1-3 were given. Fever and skin lesions
resolved within 2 weeks after the treatment
but relapsed in 1 week later. A FMD regimen
was  given  but  with  no  effect.  Then
cyclosporine  A  200  mg  together  with  pred-
nisone 90 mg per day were added. The temper-
ature  become  normal  and  skin  lesions  and
nodules  improved  1  week  later.  Then  pred-
nisone was removed (tapered off in 1 month)
and  only  cyclosporine  A  200  mg  was  taken
every day. After 1 month, this patient was dis-
charged with all the systemic symptoms and
skin  lesions  resolved.  Maintenance  dose  of
cyclosporine A was continued in 6 months and
then  removed.  The  patient’s  condition
remained in remission at 12-month follow-up
with a normal blood count; there was no evi-
dence of clinical relapse.
Discussion
The distinctive clinicopathological features
of  a  T-cell  lymphoma  involving  the  subcuta-
neous tissue were firstly described by Gonzalez
in 1991.2 It have been identified that it’s drived
from  cytotoxic  T  lymphocytes  and  named
SPTCL in the Revised European American clas-
sification of lymphoid neoplasms.5Two distinct
subtypes of SPTCL have been classiﬁed by the
cellular origins: αβ and γδ T-cell derivation.4,6
Now, SPTCL is specially refer to the cytotoxic
tumor of αβ T-cell derivation.1,7
In SPTCL, subcutaneous fat is involved that
make panniculitis-like appearance. Morpholo  -
gically,  the  lymphoma  infiltrate  involves  the
lobules of the subcutaneous tissue, resulting
in  a  typical  lobular-panniculitis-like  pattern.
The lymphoma cells are small to medium in
size with moderate pale cytoplasm; the nuclei
are round to irregular and often hyperchromat-
ic. The neoplastic cells are generally confined
to  subcutaneous  tissue  and  frequently  infil-
trate  individual  fat  cells  with  a  rim-like
arrangement  at  the  cell  border.  Dermal  and
epidermal involvement are generally absent.6
Tumor cells are most often CD8+ cytotoxic lym-
phocytes  expressing  one  or  more  cytotoxic
granule proteins including TIA-1, granzyme B,
and perforin and the αβ TCR. CD56 are are
negetive in most cases.
SPTCL typically presents with multiple sub-
cutaneous  masseson  the  extremities  and/or
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trunk.  Clinical  symptoms  include  malaise,
fatigue, myalgia and weight loss. manifesta-
tions  of  systemic  involvement  are  fever,
hepatosplenomegaly,  mucosal  ulcers  and
sometimes serosal effusions. The clinic course
may present in an indolent manner but to be
aggressive  when  the  hemophagocytic  syn-
drome(HPS) happen. HPS, a presenting fea-
ture in 37% of patients with SPTCL,7 is charac-
terized  by  fever,  cytopenia,  splenomegaly,
abnormal  liver  function,  and  the  pathologic
finding of hemophagocytosis (phagocytosis of
erythrocytes,  leukocytes,  platelets,  and  their
precursors bymacrophages) in bone marrow.8
The  appearance  of  HPS  was  thought  to  be
related to cytokine and chemokine production
by the malignant cells, perhaps in a setting of
comprised cytolytic function. This patient have
pancytopenia,  liver  function  abnormalities,
hepatosplenomegaly,  pleural  effusion,  hyper-
triglyceridemia, and coagulopathy, in keeping
with the diagnosis of relapsed SPTCL compli-
cated by HPS. 
Treatments such as systemic chemotherapy,
radiotherapy,9 stem cell transplantation10,11 and
limb amputation12 have been used since this
disease  described.  NO  standard  treatment
strategy have been made because of the rarity
of the disease. First of all, systemic steroids or
other  immunosuppressive  agents  should  be
applied  in  SPTCL  without  associated  HPS,
whereas radiotherapy should be considered in
cases  of  solitary  skin  lesions.  Multi-agent
chemotherapy may be required in cases with
progressive  disease  not  responding  to
immunosuppressive therapy or in cases with
HPS,7 but  anthracycline-based  combination
chemotherapy  (CHOP  or  CHOP-like)  were
reported  to  be  with  unsatisfactory  result.13
Other materials, such as Denileukin diftitox, a
recombinant  fusion  protein  that  combines
human  interleukin  2  and  diphtheria  toxin,
have been applied on SPTCL with challenging
outcome.14 Prednisone have been applied on
SPTCL with optimistical result although some
still  be  invalid.  In  this  patient,  prednisone
made a period of 8 months tumor release but
be  ineffective  ultimately.  Even  HPS,  a  syn-
drome  was  reported  can  be  cureed  by  pred-
nisone,15 emerging at the eighth month of the
application  of  prednisone,  proved  the  treat-
ment was aborted. CHOP together with etopo-
side, another cytostatic drug which was veri-
fied to be effective to HPS,16 so called CHOEP,
made  no  significant  effect.  SPTCL  persisted
until cyclosporine was prescribed. 
Cyclosporine,  a  calcineurin  inhibitor,  is  a
potent  immunosuppressant  that  reduces  the
production of several growth factors. In spite of
the  significantly  worse  prognosis  of  SPTCL
complicated by HPS,17 cyclosporine have been
verified  to  be  with  magical  effect  in  a  few
reports.18,19 The  mechanism  of  action  of
cyclosporin in SPTCL is also down-regulation
of cytokines. In this patient, cyclosporine (200
mg/d) made the symptoms improved within 1
week and resolved in 1 month. After 6 months,
cyclosporine  was  removed.  There  is  no  evi-
dence of clinical relapse 1 year later. 
Conclusions
There is not standard treatment to SPTCL
because of the rarity of the disease, especially
to  relapsed  phase.  We  successfully  curred  a
patien  with  relapsed  SPTCL  complicated  by
HPS. This report suggest that cyclosporine A
may be still an effictive therapy when this dis-
ease relapsed.
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